ZA977686B - Fatty acid treatment. - Google Patents

Fatty acid treatment.

Info

Publication number
ZA977686B
ZA977686B ZA9707686A ZA977686A ZA977686B ZA 977686 B ZA977686 B ZA 977686B ZA 9707686 A ZA9707686 A ZA 9707686A ZA 977686 A ZA977686 A ZA 977686A ZA 977686 B ZA977686 B ZA 977686B
Authority
ZA
South Africa
Prior art keywords
fatty acid
acid treatment
treatment
dyspraxia
precursors
Prior art date
Application number
ZA9707686A
Other languages
English (en)
Inventor
David Frederick Horrobin
Barbara Jacqueline Stordy
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of ZA977686B publication Critical patent/ZA977686B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9707686A 1996-08-27 1997-08-27 Fatty acid treatment. ZA977686B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9617847.0A GB9617847D0 (en) 1996-08-27 1996-08-27 Fatty acid treatment

Publications (1)

Publication Number Publication Date
ZA977686B true ZA977686B (en) 1998-02-27

Family

ID=10798969

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9707686A ZA977686B (en) 1996-08-27 1997-08-27 Fatty acid treatment.

Country Status (14)

Country Link
US (1) US6184251B1 (xx)
EP (1) EP0956011B1 (xx)
JP (1) JP2001504086A (xx)
KR (1) KR20000035924A (xx)
AT (1) ATE219670T1 (xx)
AU (1) AU738117B2 (xx)
CA (1) CA2263839A1 (xx)
DE (1) DE69713620D1 (xx)
GB (1) GB9617847D0 (xx)
IL (1) IL128562A0 (xx)
NO (1) NO990934L (xx)
NZ (1) NZ334260A (xx)
WO (1) WO1998008501A1 (xx)
ZA (1) ZA977686B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
CN101843610A (zh) * 2003-03-27 2010-09-29 三得利控股株式会社 花生四烯酸在制备具有使超昼夜节律正常化作用的组合物中的用途
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
DE112004001520B4 (de) * 2003-08-18 2008-04-10 Btg International Ltd. Verwendung eines Lipidglyzerids festgelegter Struktur zur Herstellung eines Medikamentes zur Behandlung der multiplen Sklerose
WO2005046668A1 (ja) * 2003-11-14 2005-05-26 Mochida Pharmaceutical Co., Ltd. 言語障害予防・治療剤
US20090215896A1 (en) * 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
EP2131679B1 (en) * 2007-02-22 2019-03-27 Children's Hospital & Research Center at Oakland Fatty acid formulations and methods of use thereof
CA2704371A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4595985A (en) 1984-08-10 1986-02-13 Sentrachem Limited Cancer treatment
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
FR2653972B1 (fr) 1989-11-07 1993-07-09 Perrier Sante Sa Phase grasse pour produits alimentaires et matieres alimentaires comparables a la creme contenant ladite phase grasse et leur procede de preparation.
GB9026648D0 (en) 1990-12-07 1991-01-23 Efamol Holdings Nutrition
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
GB9217781D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
DE4304394A1 (en) 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
CA2164291C (en) 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice

Also Published As

Publication number Publication date
WO1998008501A1 (en) 1998-03-05
AU738117B2 (en) 2001-09-06
NO990934D0 (no) 1999-02-26
EP0956011A1 (en) 1999-11-17
IL128562A0 (en) 2000-01-31
CA2263839A1 (en) 1998-03-05
ATE219670T1 (de) 2002-07-15
AU4024797A (en) 1998-03-19
NZ334260A (en) 2000-08-25
US6184251B1 (en) 2001-02-06
KR20000035924A (ko) 2000-06-26
DE69713620D1 (de) 2002-08-01
JP2001504086A (ja) 2001-03-27
GB9617847D0 (en) 1996-10-09
EP0956011B1 (en) 2002-06-26
NO990934L (no) 1999-04-14

Similar Documents

Publication Publication Date Title
GB9617847D0 (en) Fatty acid treatment
MX9709238A (es) Formulaciones farmaceuticas y de dieta para la profilaxis y tratamiento de trastornos gastrointestinales.
HK1083064A1 (en) Compositions comprising thalodimide and dexamethasone for the treatment of cancer & x9
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
PL321848A1 (en) Cell adhesion inhibitors
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
LU91145I9 (xx)
GR3015513T3 (en) Use of baclofen for the preparation of medicaments for the treatment of angina pectoris.
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
AU1628988A (en) Pharmaceutical compositions containing higher alcohols for the treatment of prostatic pathologies
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
GB9419566D0 (en) Oral prostagladins for the routine management of the third stage of labour
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
ZA875847B (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
YU29600A (sh) Korišćenje ketolida za dobijanje farmaceutskih preparata za prevenciju trombičnih arterijskih komplikacija povezanih sa arterosklerozom
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
GB9510162D0 (en) Compositions for the treatment of skin conditions
MY138319A (en) 1,5-benzodiazepine derivatives